Navigation Links
Unigene to Present at TIDES 2012
Date:5/21/2012

BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV.

TIDES 2012 is the premier conference focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the applications and alternate delivery routes of peptide therapeutics.

Target Peptide Optimization and Recombinant Manufacturing of an Orally Delivered Peptide for the Treatment of Obesity

Spotlight Presentation – Emerging Technologies Showcase – Peptides

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, May 22, 2012 at 4:30 p.m. PDT
  • Focus: Development and oral delivery of a potent lead compound for the treatment of obesity  using Unigene's Peptelligence™ technology

Alternative Delivery Platforms for Oligonucleotide and Peptide Therapeutics

Strategy Discussion Forum

  • Panelist: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Wednesday, May 23 at 4:00 p.m. PDT
  • Focus: The advantages/disadvantages of alternative delivery platforms for oligonucleotide and peptide therapeutics and their acceptability to physicians, patients and health providers

"TIDES 2012 is an ideal forum for showcasing advancements in peptide therapeutics, including Unigene's oral peptide delivery technology which we have branded as Peptelligence™," said Dr. Mehta. "Without question, the oral delivery of peptide therapeutics is the most significant recent advancement in the peptide space as it offers the opportunity to redefine the treatment regimen and increase the market potential for numerous debilitating, chronic conditions.  Unigene is at the forefront of this paradigm shift, making TIDES 2012 an extremely valuable scientific and business development event for building awareness among companies and institutions that are developing next-generation peptide compounds and looking for new ways to expand existing peptide franchises."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
2. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
3. Unigene Reports Third Quarter 2011 Financial Results
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
7. Unigene Provides 2012 Business Outlook
8. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
9. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
10. Unigene to Present at IBCs 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
11. Unigene Appoints David Moskowitz as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):